SWSatoshi Watanabe

Satoshi Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satoshi Watanabe has a total of 320 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neutrophils and CSF1 promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis

    by Kazumasa Kase, Satoshi Watanabe, Masafumi Horie, Atsushi Muto, Kazuhiko Iwasaki, Kyota Akasaki, Takafumi Kobayashi, Sachiko Arai, Hayato Koba, Kenta Yamamura, et al.

    We show that neutrophils and colony-stimulating factor 1 (CSF1) signaling promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis. We identify a distinct Csf1-expressing neutrophil subpopulation in a progressive pulmonary fibrosis model, suggesting that neutrophil-derived CSF1 may represent one potential mechanism contributing to macrophage expansion. These findings provide new mechanistic insight into how persistent macrophage accumulation contributes to progressive fibrotic remodeling.


  • Validation of claims-based algorithms for identifying selected interstitial lung disease (idiopathic interstitial pneumonias and drug-induced interstitial lung disease)

    by Kensuke Kataoka, Soko Setoguchi, Naoki Nakashima, Haoqian Chen, Melanie Rua, Tasuku Okui, Naoki Hamada, Hiroyoshi Yamauchi, Satoshi Watanabe, Motoyasu Kato, et al.

  • Open Access

    Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer

    by Yifeng Liu, Shigeki Nanjo, Yuya Murase, Sachiko Arai, Satoshi Watanabe, Takeshi Tsuda, Junya Suzuki, Hirokazu Taniguchi, Kazuhiko Shibata, Shigeki Sato, et al.

    Kirsten rat sarcoma viral oncogene (KRAS) G12C inhibitors have demonstrated clinical efficacy against KRAS G12C-mutant non-small cell lung cancer (NSCLC); however, intrinsic and acquired resistance limit their therapeutic potential. Therefore, combination strategies are needed to address these limitations. While various combination regimens are currently being tested in clinical trials, treatments tailored to specific biomarkers remain underexplored. In this study, intrinsic and acquired KRAS G12C inhibitor-resistant tumor cells were established using patient-derived xenograft (PDX) and mouse models. We identified that tumor cell-autocrine amphiregulin (AREG)-mediated epidermal growth factor receptor (EGFR) phosphorylation plays a pivotal role in both intrinsic and acquired resistance to KRAS inhibitors. Notably, the same resistance mechanism was observed in central nervous system metastatic recurrence in a leptomeningeal carcinomatosis mouse model. RNAscope in situ hybridization detected AREG mRNA in tumor tissues and may serve as a diagnostic tool for assessing AREG expression. Furthermore, combining KRAS inhibitors with EGFR tyrosine kinase inhibitors suppressed tumor growth, effectively overcoming resistance. Notably, high AREG mRNA expression was observed in three of nine tumor samples from patients harboring the KRAS G12C mutation, including two patients who exhibited a poor response to sotorasib and one patient who achieved a partial response. In conclusion, AREG-mediated EGFR activation is a key driver of resistance to KRAS inhibitors in patients with KRAS G12C-mutant NSCLC. Combining EGFR and KRAS inhibition represents a promising strategy to overcome therapeutic resistance and may enhance and prolong clinical benefit in patients.

  • Anti-MDA5 antibody-positive interstitial lung disease without prominent skin or muscle manifestations: A high-risk and potentially overlooked subgroup

    by Atsushi Muto, Satoshi Watanabe, Yuko Waseda, Seisuke Okazawa, Toshiki Kido, Keigo Saeki, Toshiyuki Kita, Hazuki Takato, Hiroki Shirasaki, Yukio Kawagishi, et al.


  • Open Access

    Influenza A infection accelerates disease-associated microglia formation during physiological aging

    by Rogan A Grant, Constance E Runyan, Grace A Minogue, Joshua S Stoolman, Satoshi Watanabe, Fei Chen, Karolina J Senkow, Luisa Cusick, Maxwell J Schleck, Radmila Nafikova, et al.

    Severe pneumonia is associated with an increased risk of cognitive decline and dementia, particularly in the elderly. Changes in microglia, the most abundant immune cell population in the brain, are also associated with cognitive decline and dementia, including the emergence of a transcriptional cell state referred to as disease-associated microglia (DAM). We sought to test the hypothesis that non-neuroinvasive influenza A virus (IAV) pneumonia results in transcriptional responses in brain microglia that drive premature expansion of DAM. Using bulk and single-cell RNA-sequencing, metabolomics, and spatial transcriptomics, we profiled neuroimmune populations in young, middle-aged, and old male mice during IAV infection and recovery. We observed an increased abundance of DAM, interferon-responsive microglia (IRM), CD4+ T cells, and CD8+ T cells in white matter regions beginning in middle age and persisting in old animals, irrespective of IAV infection. DAM exhibited a metabolic shift toward aerobic glycolysis with disrupted TCA cycling, citrulline depletion, and an elevated itaconate/α-ketoglutarate ratio. Spatial transcriptomic profiling of the human middle frontal gyrus (MFG) in normal agers, SuperAgers, and patients with dementia revealed an analogous accumulation of DAM and CD8+ T cells in white matter. IAV pneumonia induced a transient immunosenescent-like response in microglia, marked by glucocorticoid-responsive gene expression and Ccnd3 upregulation. In response to IAV pneumonia, DAM expanded in middle-aged mice, whereas old mice were elevated at baseline and were largely unaffected by IAV infection. The age-related expansion of DAM was unaffected by pharmacological depletion and repopulation of microglia with a CSF1R antagonist or genetic gain or loss of function of the phagocytic receptor MERTK, suggesting the DAM phenotype is driven by the CNS microenvironment, rather than cell-intrinsic mechanisms. Our findings suggest that IAV pneumonia induces an acute immunosenescence response in microglia and accelerates the age-dependent expansion of DAM in white matter.


  • A 72-Year-Old Man With Progressive Dyspnea and Diffuse Lung Disease.

    by Ryo Hara, Satoshi Watanabe, Yuya Murase, Tsukasa Ueda, Atsushi Muto, Kazumasa Kase, Yoshihiro Takeda, Nanao Terada, Hayato Koba, Kenta Yamamura, et al.

    A 72-year-old man with progressive dyspnea was referred to our hospital for evaluation of diffuse lung disease. His medical history was unremarkable except for a 20-year history of smoking 20 cigarettes per day. Abnormal findings were first identified on a chest radiograph during a routine medical checkup 11 months earlier. Chest CT scan showed diffuse ground-glass opacities with basilar predominant distribution and some areas of alveolar consolidation predominantly in the lower lobes. Based on clinical and radiographic findings, the patient was initially diagnosed with interstitial lung disease and treated with IV methylprednisolone pulse followed by oral prednisolone, but his condition did not improve. To exclude the possibility of infectious lung disease, empirical antibiotics were administered; however, the patient showed no clinical improvement. Subsequent treatments, including additional methylprednisolone pulses and immunosuppressive agents such as tacrolimus and cyclophosphamide, also failed to yield any significant benefit. His dyspnea progressively worsened, and home oxygen therapy was initiated 4 months before referral. Because of his deteriorating condition despite maximal medical therapy, he was referred to our hospital for comprehensive evaluation.

  • The lung as a site for the generation of anti-MDA5 antibody in clinically amyopathic dermatomyositis

    by Ryo Hara, Satoshi Watanabe, Nanao Terada, Kazumasa Kase, Atsushi Muto, Yasuhito Hamaguchi, Takashi Matsushita, Hiroko Ikeda, Tomonori Tanaka, Seiji Yano


  • Open Access

    PROGNOSTIC VALUE OF COEXISTING CONDITIONS AND COMPLICATIONS IN PLEUROPARENCHYMAL FIBROELASTOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY

    by Kazuhiko Iwasaki, Satoshi Watanabe, Kazumasa Kase, Noriyuki Ohkura, Keigo Saeki, Yuichi Tambo, Johsuke Hara, Miki Abo, Hideharu Kimura, Seiji Yano

    Background: Pleuroparenchymal fibroelastosis (PPFE) is a rare idiopathic interstitial lung disease (ILD) characterized by subpleural parenchymal fibrosis and elastosis mainly in the upper lobes. PPFE occurs in a secondary form that overlaps with underlying medical conditions or complications. This study evaluated the clinical impact of coexisting factors on the survival of patients with PPFE. Methods: Fifty-five PPFE patients were retrospectively evaluated. The patients' diagnoses were categorized as "idiopathic PPFE" with no known cause or "secondary PPFE" with underlying medical conditions or complications. The clinical characteristics and survival rates of these groups were compared. Results: Twenty-eight patients (50.9%) were diagnosed with idiopathic PPFE and 27 (49.1%) with secondary PPFE, including cases of occupational dust exposure, connective tissue disease (CTD), post-hematopoietic stem cell transplantation (HSCT), and a family history of ILD. The idiopathic and secondary PPFE groups had similar clinical features, laboratory tests, and pulmonary function profiles, including a low body mass index, normal Krebs von den Lungen-6, high surfactant protein -D, and high residual volume/total lung capacity. In the secondary PPFE group, post-HSCT was associated with a worse prognosis, and CTD was associated with better prognosis. A multivariate analysis demonstrated that post-HSCT and a reduced forced vital capacity were significantly associated with a worsened survival in patients with PPFE. Conclusions: The prognosis of PPFE is highly influenced by underlying medical conditions or complications. Patients with post-HSCT PPFE should be monitored particularly closely, as they are at higher risk of a poor prognosis than others.


  • Absence of interstitial lung disease at initial visit may predict a favorable outcome for Japanese patients with systemic sclerosis with anti–topoisomerase I antibody

    by Yasuhito Hamaguchi, Yukari Yoshimura, Motoki Horii, Natsumi Fushida, Tasuku Kitano, Kaori Sawada, Kyosuke Oishi, Shintaro Maeda, Satoshi Watanabe, Takashi Matsushita

    Interstitial lung disease (ILD) is recognized a prognostic factor and leading cause of death in patients with systemic sclerosis (SSc). The aim of the present study is to clarify factors at an initial visit that are associated with the deterioration of ILD in SSc patients with anti-topoisomerase I (anti-topo I) antibodies. This was a single-center, retrospective, observational study. Fifty-three consecutive SSc patients with anti-topo I antibodies were included in this study. Of the 53 patients, 43 had ILD at their initial visit, whereas 10 did not. We examined the clinical and immunological factors at an initial visit that were associated with the deterioration of ILD. The deterioration of ILD was defined as the administration of intravenous cyclophosphamide (IVCY) therapy. In this cohort, 45 (85%) patients had ILD at the time of the final observation, and only two who did not have ILD at their initial visit developed ILD during the follow-up period. Until the final observation, 26 (49%) patients received IVCY therapy for the progression of ILD. The age at onset, disease duration, SSc subtype, and skin score were similar between patients with and those without IVCY therapy. Approximately 60% (26 of 43) of patients with ILD at their initial visit received IVCY therapy. On the other hand, none of the 10 patients without ILD at their initial visit received IVCY therapy. Our multivariate analyses using Cox proportional hazards regression model revealed that the presence of ILD at an initial visit was an independent factor associated with the introduction of IVCY therapy (odds ratio, 2.8e+7 [95% confidence interval, 1.8e+17-uncalculated], p = 0.0048). Although anti-topo I antibodies are strongly associated with ILD, it was unlikely for SSc patients with anti-topo I antibodies to receive IVCY therapy when they did not have ILD at an initial visit.

  • Open Access

    THU069 Growth Hormone Secretion And Serum High-sensitivity C-reactive Protein Levels In Adult Patients With Non-functioning Pituitary Tumors

    by Yasufumi Seki, Satoshi Morimoto, Kanako Bokuda, Daisuke Watanabe, Satoshi Watanabe, Kaoru Yamashita, Noriyoshi Takano, Atsuhiro Ichihara

    Disclosure: Y. Seki: None. S. Morimoto: None. K. Bokuda: None. D. Watanabe: None. S. Watanabe: None. K. Yamashita: None. N. Takano: None. A. Ichihara: None. Background: Growth hormone (GH) deficiency, which causes visceral obesity and non-alcohol fatty liver disease, increases cardiovascular event risks. Serum high-sensitivity C-reactive protein (hs-CRP) levels has been reported to estimate those risks. GH supplementation therapy was reported to decrease the serum hs-CRP levels in GH deficient patients, however, the association between GH secretion and serum hs-CRP levels have been unclear. Patients and Methods: We retrospectively reviewed charts of the patients with non-functioning pituitary adenoma and Rathke’s cysts who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests to assess GH secretion, and investigated the association between GH secretion and background characteristics. Patients who had a history of pituitary surgery, severe renal insufficiency or active inflammatory diseases, or received GH supplementation therapy were excluded. Results: Among 171 patients (100 NFPA and 71 Rathke’s cysts), 55 (32%) presented severe GH deficiency, as diagnosed using GHRP-2 tests. Serum hs-CRP levels were significantly higher in the patients with severe GH deficiency than in those without severe GH deficiency (754 [393—1330] vs 249 [113—537] ng/mL, P < 0.001). Serum hs-CRP levels were significantly correlated with logarithm of peak GH response to GHRP-2 (r = -0.50, P < 0.001), but not with IGF-1 SD score (r = -0.10, P = 0.21). In the multiple regression analysis, peak GH response to GHRP-2 was a significant variable for determining serum hs-CRP levels (β = -0.340, P = 0.001) after adjustment with age, sex, BMI, smoking habit, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, abnormal liver function, and other pituitary hormone deficiencies. Severe GH deficiency were significantly associated with for serum hs-CRP levels higher than 1000 ng/mL (Odds ratio, 2.58 ;95% Confidence interval 1.15-5.78) when adjusted for obesity and abnormal liver function. Conclusion: GH secretion was significantly and negatively associated with serum hs-CRP levels independent of atherosclerotic risk factors, metabolic complications of GH deficiency, and other anterior pituitary hormone secretions. Presentation: Thursday, June 15, 2023